Enara-5/Enara-20

Enalapril maleate

HTN. Symptomatic heart failure.

HTN Adult Initially 5 mg once daily. Decrease to 2.5 mg daily in patients taking diuretics. Usual dose: 10-40 mg daily as single or 2 divided doses. Max: 40 mg daily. Ped <16 yr Initially 0.08 mg/kg once daily, may increase up to 5 mg daily. Symptomatic heart failure Initially 2.5 mg bid. 5 mg Usual dose: 5-20 mg daily as single or 2 divided doses. Max: 40 mg daily. 20 mg Usual dose: 10-40 mg daily as single or 2 divided doses. Max: 2.5-20 mg daily.

May be taken with or without food.

Hypersensitivity to enalapril maleate or ACE inhibitor. History of angioedema related to ACE inhibitor therapy & hereditary or idiopathic edema; DM. Concomitant use w/ aliskiren. Co-administration w/ or w/in 36 hr of switching to or from neprilysin inhibitor eg, sacubitril.

Discontinue if angioedema is associated w/ laryngeal edema. Symptomatic hypotension w/ or w/o syncope; hyperkalemia; chronic cough; angioedema. Patients w/ Na depletion or hypovolemia, receiving diuretics & undergoing dialysis. Evaluate renal function prior to initiation of therapy; serum creatinine & electrolyte conc prior to & 1 wk following initiation of therapy in patients w/ CHF. Renal impairment. Pregnancy & lactation. Not recommended in neonates or ped w/ GFR <30 mL/min/1.73 m².

Chest pain, hypotension, orthostatic hypotension, syncope; dizziness, fatigue, headache; skin rash; abdominal pain, anorexia, constipation, diarrhea, dysgeusia, nausea, vomiting; weakness; increased serum creatinine, renal insufficiency; bronchitis, cough, dyspnea.

Avoid concomitant use w/ bromperidol, sacubitril. Increased effect/toxicity of allopurinol, amifostine, angiotensin II, 2nd gen antipsychotics, azathioprine, bromperidol, systemic ciprofloxacin, drospirenone, duloxetine, ferric gluconate, ferric hydroxide polymaltose complex, succinylated gelatin, gold Na thiomalate, grass pollen allergen extr, hypotension-associated agents, Fe dextran complex, levodopa, lithium, nitroprusside, NSAIDs, pholcodine, pregabalin, sacubitril, Na phosphate. Increased effect w/ alfuzosin, aliskiren, ARB, barbiturates, benperidol, brigatinib, topical brimonidine, canagliflozin, dapoxetine, diazoxide, dipeptidyl peptidase-IV inhibitors, eplerenone, everolimus, heparin, LMWH, herbs w/ hypotensive properties, loop diuretics, lormetazepam, molsidomine, naftopidil, nicergoline, nicorandil, obinutuzumab, pentoxifylline, phosphodiesterase-5 inhibitors, K salts, K-sparing diuretics, prostacyclin analogues, quinagolide, salicylates, sirolimus, temsirolimus, thiazide & thiazide-like diuretics, tizanidine, tolvaptan, trimethoprim. Decreased effect w/ amphetamines, aprotinin, brigatinib, bromperidol, herbs w/ hypotensive properties, icatibant, lanthanum, methylphenidate, NSAIDs, salicylates, yohimbine.

ACE Inhibitors/Direct Renin Inhibitors

C09AA02 - enalapril ; Belongs to the class of ACE inhibitors. Used in the treatment of cardiovascular disease.

D